Invited Speakers:
Program:
DISCOVERY AND DEVELOPMENT OF TUMOR VACCINES-CS796
Organizer: Steven Gillis-Corixa Corp
May 6-12, 1996; Taos, New Mexico
Mon. 5/6-Registration-Orientation-KEYNOTE ADDRESS: L. Old , Ludwig Inst Cancer Rsch,
"The Re-birth of Tumor Immunology"
Tue. 5/7-VACCINE APPROACHES TO MELANOMA THERAPY I: M. Kripke , MD
Anderson Cancer Ctr, "Whole Tumor Cells as Melanoma Vaccines"; T. Boon , Ludwig Inst Cancer
Rsch, "MAGE Peptide Tumor Vaccines"; A. Bakker , Univ Hospital-Nijmegen, "gp100-A
Melanoma Targe t Antigen"; R. Rose , CYTEL, "MAGE 3 Tumor Vaccines"-POSTER SESSION
1-VACCINE APPROACHES TO MELANOMA THERAPY II: D. Hunt, Univ Virginia, "Direct
Identification of Tumor Antigens by Mass Spectrometry"; P. Livingston , Mem Sloan-Kettering
Cancer Ctr, "GM-2 Vaccine Therapy for Melanoma"; M. Mitchell , Univ Southern California,
"Melanoma Cell Based Vaccines"
Wed. 5/8-TUMOR VACCINE TARGETS I: Lynn Spitler, Jenner Technologies, "Prostate Specific
Antigen as a Cancer Vaccine"; Albert DeLeo , Univ Pittsburgh, "The gp110 Family of Tumor
Antigens"; O. Finn , Univ Pittsburgh, "Muc-1 Tumor Vaccine"; M. Longenecker, BIOMIRA,
"Cancer Vaccines Which Target Carbohydrate, Glycopeptide and Peptide Mucin
Epitopes"-POSTER SESSION 2-TUMOR VACCINE TARGETS II: J. Schlom, Nat'l Inst Hlth,
"CEA as a Tumor Vaccine Target"; W. Martin Kast , Loyola Univ Sch Med, "Papilloma Virus P
eptides as Cervical Cancer Vaccines"; L. Kwak , Nat'l Cancer Inst, "Idiotypes as Vaccines for
Lymphoma/Myeloma"
Thur. 5/9-WHOLE CELL/CELL LYSATE CLINICAL TRIALS: J. Bystryn , New York Univ,
"Active Immunotherapy with Partially Purified Tumor Antigens"; H. Hoover, Lehigh Valley Hosp,
"Autologous Tumor Cells as Vaccines"; Speaker to be Announced-POSTER SESSION 3-HER
-2/NEU AS A VACCINE TARGET: M. Cheever , Univ Washington, "Her-2/Neu Peptide
Vaccines"; M. Shepherd , Genentech, "Anti-Her-2/Neu Antibody Therapy"; P. Guyre, Dartmouth
Med Sch, "Fc Receptor-Targeted Fusion Proteins: A Novel and Effective Antigen Deliver y
System"; D. Ring , Chiron, "Her-2/Neu Bi-Specific Antibodies as Tumor Vaccines"
Fri. 5/10-VACCINE DELIVERY APPROACHES: K. Rock, Dana Farber Cancer Inst,
"Generation CTL Immunity by Targeting Protein Antigens into the MHC Class I Pathway of
Presentation"; P. Srivastava , Fordham Univ, "Use of Heat Shock Proteins as Vaccine Delivery T
echnology"; Richard Mulligan , Univ Pittsburgh, "Viral Vectors as Carriers of Cancer Vaccines"; V.
Zurawski , Apollon, "Injected Plasmid DNA as a Method for Producing an Anti-Tumor Immune
Response"; Ralph Steinman , Rockefeller Univ, "Antigen-Pulsed Dendr itic Cells as Carriers of
Tumor Vaccines"
-POSTER SESSION 4-CYTOKINES AS VACCINE ADJUVANTS: Speaker to be
Announced; R. Levy , Stanford Univ, "gm-CSF Fusion Protein Cancer Vaccines"; E. Lord, Univ
Rochester, "Comparative Efficacy of a Variety of Cytokines to Function as Co-Stimulants in
Producin g Immunity to Poorly Immunogenic Tumors"; M. Lotze , Univ Pittsburgh, "Interleukin 12
as a Tumor Vaccine Adjuvant"
Sat. 5/11-NEWLY DISCOVERED TUMOR ANTIGENS I: S. Gillis, Corixa Corp, "A
Retrovirus-like Sequence Associated witth Human Breast Carcinoma"; T. Rose, Univ
Washington"Closely Related Glycoprotein B and DNA Polymerase Genes from Kaposi's
Sarcoma-Associated a nd Retroperitoneal Fibromatosis-Associated Herpes Viruses"; J. Morre,
Purdue Univ, "tNOX-A Tumor Cell Surface NADH Oxidase Associated with Malignancy"; P.
Fisher , Columbia Univ, "Antibody Masking Approaches to Tumor Antigen Discovery"
-NEWLY DISCOVERED TUMOR ANGTIGENS II: Speakers to be Announced-Banquet
(Please note: There are NO POSTERS on banquet day.)
Sun. 5/12-Departure
Registration :
Cambridge Symposia
1037 Chestnut Street
Newton Upper Falls, MA 02164
Phone:(617)630-1399
Fax:(617)630-1395
Deadline for Abstracts: January 10, 1996
Email for Requests and Registration: symposia@cambridge.org